{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:45:58Z","timestamp":1781829958458,"version":"3.54.5"},"reference-count":26,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,7,1]]},"abstract":"<jats:p>Acute changes in thyroid hormone levels before and after radioiodine therapy for Graves\u2019 disease were compared in 42 patients randomized to receive either antithyroid drug pretreatment or no pretreatment. Five patients (11.9%), including 3 in the pretreatment arm and 2 in the no pretreatment arm experienced a late exacerbation of thyrotoxicosis after radioiodine therapy. The majority (19 of 21, 90.5%) of pretreated patients experienced a transient increase in free T4 and free T3 after discontinuation of antithyroid drugs, with little further elevation after radioiodine therapy. After stopping antithyroid drugs and before radioiodine administration, mean serum free T4 values rose from 14.7 \u00b1 6.9 to 21.6 \u00b1 12.1 pmol\/L, representing a 46.9% increase, whereas serum free T3 levels rose from 4.9\u00b1 1.7 to 8.1 \u00b1 6.3 pmol\/L, representing a 65.3% increase. The average pretreated patient experienced a 52.4% increase [95% confidence interval (CI), +26.4% to +78.5%] in free T4 and a 61.8% increase (95% CI, +23.5% to +100.0%) in free T3. Conversely, the majority (19 of 21, 90.5%) of nonpretreated patients experienced a rapid decline in thyroid hormone levels after radioiodine treatment. Over the 14 days after radioiodine therapy mean free T4 values in nonpretreated patients fell from 85.8 \u00b1 60.4 to 58.0 \u00b1 76.5 pmol\/L, representing a 32.4% decrease, whereas mean free T3 levels fell from 16.1 \u00b1 8.0 to 10.8 \u00b1 11.1 pmol\/L, representing a 32.9% decrease. The average nonpretreated patient experienced a 20.6% decrease (95% CI, \u221247.3% to +7.0%) in free T4 and a 24.3% decrease (95% CI, \u22121.2% to \u221247.4%) in free T3 during this time period. Excluding 2 patients with a late exacerbation after radioiodine, 19 nonpretreated patients experienced a decrease in mean free T4 values from 76.8 \u00b1 46.6 to 36.6 \u00b1 19.8 pmol\/L, representing a 52.3% decrease, whereas mean free T3 levels fell from 15.5 \u00b1 7.7 to 7.8 \u00b1 3.6 pmol\/L, representing a 49.7% decrease. The average decrease in free T4 levels among this subgroup of patients was 30.1% (95% CI, \u22124.6% to \u221255.6%), whereas the average decrease in free T3 was 34.4% (95% CI, \u221213.7% to \u221255.1%). High levels of TSH receptor autoantibodies at diagnosis were associated with an acute worsening of thyrotoxicosis after stopping antithyroid drug pretreatment. We conclude that pretreatment with antithyroid drugs does not protect against worsening thyrotoxicosis after radioiodine, but may allow such patients to start from a lower baseline level should an aggravation in thyrotoxicosis occur. The findings support the recommendation that most patients with Graves\u2019 disease do not require antithyroid drug pretreatment before receiving radioiodine.<\/jats:p>","DOI":"10.1210\/jcem.86.7.7639","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:07:11Z","timestamp":1389200831000},"page":"3016-3021","source":"Crossref","is-referenced-by-count":7,"title":["The Effect of Antithyroid Drug Pretreatment on Acute Changes in Thyroid Hormone Levels after 131I Ablation for Graves\u2019 Disease1"],"prefix":"10.1210","volume":"86","author":[{"given":"H. B.","family":"Burch","sequence":"first","affiliation":[{"name":"Endocrine-Metabolic Service, Department of Medicine (H.B.B.), Washington, D.C. 20307-5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. L.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigation (B.L.S., R.H.), Washington, D.C. 20307-5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Department of Medicine, Sinai Hospital (D.S.C., N.W.), Baltimore, Maryland 20010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Service, Department of Radiology (P.F.), Walter Reed Army Medical Center, Washington, D.C. 20307-5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Walpert","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Department of Medicine, Sinai Hospital (D.S.C., N.W.), Baltimore, Maryland 20010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigation (B.L.S., R.H.), Washington, D.C. 20307-5001"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071618575913400_R1","first-page":"213","volume":"7","year":"1997"},{"key":"2020071618575913400_R2","author":"Livolsi","year":"1990"},{"key":"2020071618575913400_R3","first-page":"353","volume":"75","author":"McDermott","year":"1983"},{"key":"2020071618575913400_R4","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1210\/jcem-70-6-1518","article-title":"Current trends in the management of Graves\u2019 disease.","volume":"70","author":"Solomon","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618575913400_R5","first-page":"225","volume":"27","year":"1998"},{"key":"2020071618575913400_R6","first-page":"425","volume":"47","author":"Hancock","year":"1997"},{"key":"2020071618575913400_R7","first-page":"831","volume":"88","year":"1995"},{"key":"2020071618575913400_R8","first-page":"810","volume":"23","author":"Turton","year":"1998"},{"key":"2020071618575913400_R9","first-page":"553","volume":"121","author":"Burch","year":"1994"},{"key":"2020071618575913400_R10"},{"key":"2020071618575913400_R11","first-page":"64","article-title":"Hyperthyroidism.","volume":"5","author":"Burch","year":"1994","journal-title":"Curr Ther Endocrinol Metab"},{"key":"2020071618575913400_R12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jcem-11-11-1296","article-title":"Responses to radioactive iodine therapy in hyperthyroidism, with special reference to cardiac problems.","volume":"11","author":"Maloof","year":"1951","journal-title":"J Clin Endocrinol"},{"key":"2020071618575913400_R13","first-page":"1231","volume":"2","author":"Wise","year":"1975"},{"key":"2020071618575913400_R14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(76)92869-5","article-title":"Thyroid storm and iodine-131 treatment.","volume":"2","author":"Creutzig","year":"1976","journal-title":"Lancet"},{"key":"2020071618575913400_R15","first-page":"580","article-title":"Late and transient increases in free T4 after radioiodine treatment for Graves\u2019 disease. J Endocrinol.","volume":"20","author":"Stensvold","year":"1997","journal-title":"Invest"},{"key":"2020071618575913400_R16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0300-2977(99)00066-2","article-title":"Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs.","volume":"55","author":"Koornstra","year":"1999","journal-title":"Neth J Med"},{"key":"2020071618575913400_R17","first-page":"4012","article-title":"Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves\u2019 hyperthyroidism.","volume":"84","author":"Andrade","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618575913400_R18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0001-2998(78)80010-5","article-title":"The treatment of hyperthyroidism with iodine-131.","volume":"8","year":"1978","journal-title":"Semin Nucl Med"},{"key":"2020071618575913400_R19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis. Thyroid storm.","volume":"22","author":"Burch","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071618575913400_R20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/jcem.83.2.4538","article-title":"Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism.","volume":"83","author":"Imseis","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618575913400_R21","author":"Taurog","year":"2000"},{"key":"2020071618575913400_R22","first-page":"1229","article-title":"Success rate of radioiodine therapy in Graves\u2019 disease: the influence of thyrostatic medication.","volume":"84","author":"Sabri","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618575913400_R23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197102112840616","article-title":"Use of propranolol in thyrotoxicosis.","volume":"284","author":"Horowitz","year":"1971","journal-title":"N Engl J Med"},{"key":"2020071618575913400_R24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1995.tb02039.x","article-title":"Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?","volume":"43","author":"Jarlov","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618575913400_R25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1410117","article-title":"Optimized radioiodine therapy of Graves\u2019 disease: analysis of the delivered dose and of other possible factors affecting outcome.","volume":"141","author":"Catargi","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"2020071618575913400_R26","first-page":"247","volume":"7","author":"Peters","year":"1997"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/7\/3016\/9165551\/jcem3016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/7\/3016\/9165551\/jcem3016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:09:28Z","timestamp":1594958968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/86\/7\/3016\/2848373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,1]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.86.7.7639","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7,1]]}}}